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Abstract
Background: Chlamydia trachomatis is a human pathogen which causes a number of pathologies, including
genital tract infections in women that can result in tubal infertility. Prevention of infection and disease control
might be achieved through vaccination; however, a safe, efficacious and cost-effective vaccine against C. trachomatis
infection remains an unmet medical need. C. trachomatis major outer membrane protein (MOMP), a β-barrel integral
outer membrane protein, is the most abundant antigen in the outer membrane of the bacterium and has been
evaluated as a subunit vaccine candidate. Recombinant MOMP (rMOMP) expressed in E. coli cytoplasm forms inclusion
bodies and rMOMP extracted from inclusion bodies results in a reduced level of protection compared to the native
MOMP in a mouse challenge model.
Results: We sought to target the recombinant expression of MOMP to the E. coli outer membrane (OM).
Successful surface expression was achieved with codon harmonization, utilization of low copy number vectors
and promoters with moderate strength, suitable leader sequences and optimization of cell culture conditions.
rMOMP was extracted from E. coli outer membrane, purified, and characterized biophysically. The OM expressed
and purified rMOMP is immunogenic in mice and elicits antibodies that react to the native antigen, Chlamydia
elementary body (EB).
Conclusions: C. trachomatis MOMP was functionally expressed on the surface of E. coli outer membrane. The
OM expressed and purified rMOMP elicits antibodies that react to the native antigen, Chlamydia EB, in a mouse
immunogenicity model. Surface expression of MOMP could provide useful reagents for vaccine research, and the
methodology could serve as a platform to produce other outer membrane proteins recombinantly.
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Background
Chlamydia trachomatis is an obligate intracellular
Gram-negative bacterium responsible for a number of
pathologies. Different strains of C. trachomatis are
separated into multiple serovars based on serological
differences in the Chlamydia major outer membrane
protein (MOMP) [1, 2]. C. trachomatis serovars A, B,
Ba, and C are responsible for ocular trachoma which
can cause conjunctivitis, conjunctival scarring and cor-
neal scarring. Serovars L1, L2 and L3 are responsible
for lymphogranuloma venereum, which can cause sub-
mucosa and lymph-node invasion, with necrotizing
granulomas and fibrosis. Serovars D, Da, E, F, G, H, I,
Ia, J, Ja and K are responsible for oculogenital disease
which can cause cervicitis, urethritis, endometritis,
pelvic inflammatory disease, tubal infertility, ectopic
pregnancy, neonatal conjunctivitis and infant pneumonia
[3, 4]. C. trachomatis infection is one of the most common
sexually transmitted diseases in the world and imposes a
significant medical and economic burden [5–7]. There-
fore, a prophylactic vaccine is desirable to prevent C.
trachomatis related diseases.
Past vaccine candidates comprised of formalin-
inactivated Chlamydia trachomatis were only able to
elicit short lived protection [8]. The subunit vaccine
approach has been investigated as an alternative. The
Chlamydia bacterium exists outside the host cell as a
metabolically inactive infectious elementary body (EB)
and the Chlamydia MOMP accounts for about 60 %
of the mass of the outer membrane of EBs [9, 10].
Antibodies against MOMP can neutralize infectivity of
EBs and T cell epitopes have also been identified in
MOMP [11, 12]. Therefore, MOMP has been an attractive
subunit vaccine candidate against Chlamydia infection for
many researchers [13–18]. Native MOMP (nMOMP) anti-
gen isolated from EBs induced a protective immune re-
sponse to a C. trachomatis genital challenge infection in a
mouse model [14, 15]. However, development of a robust,
cost-effective commercial manufacturing process based
on the use of native MOMP can be challenging. Recom-
binant expression of a vaccine antigen is an alternative
method to purification of native antigen from infected
cells, and may be easier to scale-up to a commercial
manufacturing level.
Chlamydia MOMPs are part of a larger family of gen-
etically related outer membrane proteins (the OmpA
family) that are heat-modifiable, surface exposed porin
proteins [19]. OmpA proteins have a structurally similar
N-terminal domain that is embedded in the bacterial
outer membrane. OmpA proteins have been targeted as
vaccine candidates because of their surface exposure, high
immunogenicity, and role in the interaction between
the bacteria and their host cells. Unlike most outer
membrane β-barrel proteins, MOMP is cysteine rich
and was predicted to be a 16 stranded β-barrel outer
membrane protein [20, 21]. Recombinantly expressed
MOMP (rMOMP) has been explored as a vaccine can-
didate. rMOMP expressed without a leader sequence
forms inclusion bodies in the cytoplasm of E. coli and
rMOMP extracted from inclusion bodies resulted in a
reduced level of protection compared to the native
MOMP in a mouse challenge model [22, 23]. This may
be due to the extracted and refolded rMOMP not hav-
ing the correct conformation. Thus as an alternative, an
outer membrane (OM) expressed rMOMP may attain
the correct conformation and enhance the vaccine effi-
cacy. Previous OM expression of rMOMP in E. coli
resulted in significant reduction in cell viability [22, 24].
Findley et al. has shown improved surface expression of
rMOMP, however did not report immunogenicity of
the expressed OM rMOMP in an animal model [25]. In
this study, expression of rMOMP in E. coli outer mem-
brane was optimized by using a number of strategies
including rMOMP gene codon harmonization, utilization
of low copy number vectors and promoters with moderate
strength, evaluation of leader sequences and optimization
of cell culture conditions. rMOMP was extracted, purified
and biophysically characterized. We show here that E. coli
OM expressed rMOMP possessed β-barrel structure and
elicits serum antibodies that react to the native antigen,
Chlamydia elementary body, in a mouse immunogenicity
model.
Methods
Codon harmonization of the Chlamydia MOMP gene for
recombinant expression
Nucleotide sequences of the gene encoding MOMP were
retrieved from Merck internal website CMR (Comprehen-
sive Microbial Resources) for the following strains: C.
muridarum Nigg (strain MoPn) ORF TC0052 (GenBank
Gene ID: 1245581; Protein link P75024.1); C. trachomatis
strain D/UW-3/CX CT ORF TC_681 Serovar D (GenBank
Gene ID: 884473; Protein link NP_220200.1); and C. tra-
chomatis strain E/12–94 ORF O175_03780 Serovar E
(GenBank Gene ID: 16635280; Protein link P17451).
Amino acid sequences consisting of a secretion leader and
the mature MOMP protein (Table 1) were codon harmo-
nized [26, 27]. In brief, the codon usage data for Chla-
mydia (native host) and E. coli (expression host) were
obtained from the Codon Usage Database (http://www.ka-
zusa.or.jp/codon/). For each species, the strain with the
most codon usage data available was selected as a repre-
sentative. The codon usage frequency for both native and
expression hosts was then calculated and a reference data-
base was generated. We first identified the amino acid res-
idues for which the rare codons were used in the native
host, and the corresponding rare codon in expression host
was selected for those residues. For the remaining
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residues, the codon in the expression host that has the
closest frequency to the corresponding codon in the native
host was selected, and the harmonized gene sequence for
Chlamydia MOMP was then generated. NdeI and XhoI
sites were avoided in the sequences for subsequent
cloning.
Cloning and expression of recombinant Chlamydia MOMP
The harmonized gene sequences with flanking NdeI
and XhoI restriction enzyme sites were synthesized and
cloned into the pUC57 cloning vector (Genewiz). The
synthesized genes were excised from pUC57 vector
through NdeI and XhoI resitriction sites. The excised
DNA fragments were ligated into the pAVE029 expres-
sion vector (MSD Biologics UK) using T4 DNA ligase
(Promega) for 4 h at 16 °C. Ligated plasmids were
transformed into competent cells DH5α (Invitrogen)
and grown on LB agar plates with 10 μg/mL tetracyc-
line. Colonies harboring the recombinant plasmid were
identified by PCR and confirmed by sequencing using
pAVE029 vector specific primers for 5′end of the gene
(ppop40 primer ATTCTGCATTCACTGGCCGAGG)
and 3′end of the gene (T7 Term standard sequencing
primer GCTAGTTATTGCTCAGCGG). The sequence-
confirmed positive colonies were propagated in LB
medium with 10 μg/mL of tetracycline and plasmid
DNA was isolated from the cell cultures with HiSpeed
Maxi Kit (Qiagen).
The recombinant plasmid DNA was transformed by
electroporation into an expression host strain E. coli
K12 W25113 using a Bio-Rad GenePulser. Transformed
cells were plated on LB Agar plates with 10 μg/mL tetra-
cycline and grown overnight at 37 °C. Single colonies
were picked and inoculated into Cinnabar media
(Teknova) with 10 μg/mL of tetracycline and grown at
37 °C with shaking at 250 rpm until OD600 reaches to
mid log phase (~0.5). 0.4 mM IPTG was added into the
cell culture for induction and the cell culture was incu-
bated for 4 h at 30 °C with shaking. The cell cultures
were then characterized by whole cell flow cytome-
try antibody binding, SDS-PAGE, and western blot
analyses.
Whole cell flow cytometry antibody binding
50 μL of E. coli cell culture (at ~1x109 cells/mL) that
recombinantly expresses Chlamydia MOMP was incu-
bated with 50 μL of mouse sera generated in-house
against Chlamydia EBs at a dilution of 1:250 for 1 h at
room temperature in a 96 well plate. After incubation,
the cells were washed with 1 mL phosphate buffered sa-
line (PBS) and stained with 100 μL of a fluorescence la-
beled secondary antibody (Alexa Fluor-488 F(ab)’2
fragment of goat anti-mouse IgG (H + L), Life Tech-
nologies) at a dilution of 1:100. The stained cells were
washed twice and re-suspended in PBS for flow cyto-
metric analysis (Guava Technologies). Data analyses
were performed with CytoSoft 5.3 software (Guava
Technologies).
SDS-PAGE and western blot
E. coli cell culture (~1x109 cells) that recombinantly
expresses Chlamydia MOMP was treated with SDS load-
ing buffer with reducing agent (Invitrogen). Samples were
applied to NuPAGE (Invitrogen) gel electrophoresis.
NuPAGE gel was stained with Gel Code Blue staining
solution (Pierce). For western blot, samples were applied
to gel electrophoresis and then electro-transferred onto
nitrocellulose membranes (Life Technologies). The mem-
branes were incubated with mouse sera against Chlamydia
EBs (or other specific primary antibodies) followed by a
fluorescence conjugated goat anti-mouse secondary anti-
body (IRDye 680LT, Licor). Image was acquired and ana-
lyzed by a LI-COR Odyssey imaging system.
Purification of Chlamydia MOMP
E. coli cell culture was grown in Cinnabar media
(Teknova) and induced by IPTG as described above.
Cell culture was harvested by centrifugation at 12,000 x g
Table 1 Evaluation of Secretion Leader Sequences
Secretion Leader Amino Acid Sequences rMOMP Surface Expression
Cm-MOMP CtD-MOMP CtE-MOMP
Native Cm-MOMP MKKLLKSVLAFAVLGSASSLHA + - -
Native CtD/CtE-MOMP MKKLLKSVLVFAALGSASSLQA ND - -
Shigella flexneri (SopA) MKSKFLVLALCVPAIFTTHA ND ND +
Salmonella enterica (PgtE) MKTHVIAVMIIAVFSESVYA ND ND +
Yersinia pestis (Pla) MKKSSIVATIITILSGSANA ND ND +
E. coli OmpP MQTKLLAIMLAAPVVFSSQEASA ND ND +
E. coli OmpA MKKTAIAIAVALAGFATVAQA + ND +
pectate lyase B of Erwinia carotovora CE (PelB) MKYLLPTAAAGLLLLAAQPAMA + + +
ND: Not Determined
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for 15 min. Cell pellets were weighed and resuspended in
9 volumes (v/w) of 50 mM Tris-Cl pH 8.0 buffer with
EDTA free protease inhibitor (Roche, 1 tab per 100 mL
buffer). Cells were disrupted by microfluidization and
undisrupted cells were pelleted and removed by centrifu-
gation at 9700 x g for 15 min. Membrane fraction was pel-
leted by centrifugation of the cleared disrupted cells at
23800 x g for 90 min and washed with high salt buffer
(1 M NaCl, 0.05 % tween20) followed by another centrifu-
gation at 23800 x g for 90 min. To remove the bacterial
inner membrane, washed membrane fraction was resus-
pended in buffer A (20 mM Tris-Cl pH 8.0, 1 mM EDTA)
with 1 % Triton X-100, incubated at room temperature
for 15 min followed by ultracentrifugation at 120,000 x g
for 40 min. To remove bacterial outer membrane proteins
other than recombinant MOMP, pellets were resuspended
by buffer A with 3 % β-octyl-glucoside, incubated at room
temperature for 1 h followed by ultracentrifugation at
120,000 x g for 40 min. rMOMP was extracted by resus-
pending the pellets in buffer A with 1 % sarkosyl and
5 mM DTT, incubated at room temperature for 2 h
followed by ultracentrifugation at 120,000 x g for 40 min.
Extracted rMOMP was subjected to size exclusion chro-
matography (Sephacryl S300, GE healthcare) in a buffer
containing 10 mM Hepes pH 7.3, 150 mM NaCl, 0.1 %
zwittergent 3–14. Eluted rMOMP was further purified
with ion exchange chromatography (Hitrap Q FF, GE
healthcare). Purified rMOMP fractions were pooled and
stored at 4 °C. Native MOMP was purified from infected
HELA cells similarly as previously described [28]. Briefly,
nMOMP was extracted from intact Chlamydia-infected
HELA cells using CHAPS and zwittergent 3–14 with
100 mM DTT and sonication, and further purified with
hydroxyapatite chromatography, tangential flow filtration,
and anion exchange chromatography.
Circular dichroism spectroscopy
Circular dichroism spectra were acquired on a Chirascan
spectrometer (Applied Photophysics LtD, UK). Samples
were analyzed undiluted using a quartz cuvette with
0.5 mm pathlength. The temperature control was set to
20 °C. The bandwidth was set to 1 nm and data points
between 200 nm and 280 nm were acquired in 1 nm
intervals. Scans below 200 nm exceeded the allowable
photomultiplier voltage and were not recorded. Sample
and buffer spectra were acquired after 10 min of
temperature equilibration applying three technical rep-
licates, respectively. Average buffer spectra were sub-
tracted from sample spectra. Resulting data points were
smoothed with the Savitzky-Golay algorithm (polyno-
mial order 2, two data points to left and right) using
the Origin Pro 7.5 SR7 software package (Origin Lab
Corporation).
Cell culture and propagation of Chlamydiae
All cell lines and Chlamydia strains were obtained from
ATCC (Manassas, VA). HeLa 229 cells were used for
propagation of all strains. HeLa 229 cells were grown in
Eagle’s Minimal Essential Medium (ATCC) supplemented
with 10 % heat-inactivated fetal bovine serum (Hyclone),
50 μg/mL vancomycin (Sigma), and 10 μg/mL gentamicin
(Gibco). Host cells were seeded into tissue culture flasks
at a cell density of 5 × 105 cells/mL and incubated over-
night at 37 °C in 5 % CO2 to achieve a confluent mono-
layer. Cell monolayers were infected with C. trachomatis
(Ct) strain D/UW-2/Cx stock diluted in sucrose–phos-
phate–glutamate (SPG) buffer and cultured for 72 h. The
Chlamydiae were harvested from the infected cells and
purified by centrifugation through 30 % Renograffin
(Bracco Diagnostics) and stored frozen at -80 °C.
Mouse immunization and challenge
Female C57BL/6 mice (Taconic Farms) were used at 6 to
8 weeks of age, and food and water were provided ad
libitum. All animal procedures were in accordance with
government and institutional guidelines for animal
health and well-being, and were approved by the Merck
Institutional Animal Care and Use Committee.
Animals were immunized by subcutaneous (s.c.) routes
with rMOMP or nMOMP (10 μg/mouse/immunization)
in combination with an adjuvant containing 50 μg CpG
and 70 % (w/v) Montanide ISA 720 VG (SEPPIC Inc.,
Coley Pharmaceutical Group). Live EB groups were
immunized with 1x106 EB in SPG per mouse by intra-
peritoneal (i.p.) route. Adjuvant control groups were
administered with a combination of CpG and Montanide
ISA 720 VG only. Immunizations were administered on
days 0, 20 and 30.
Prior to the first immunization and two weeks follow-
ing the final immunization, tail bleeds were performed
with blood collected in BD Microtainer® Serum Separ-
ator Tubes (Becton, Dickinson and Company). Blood
samples were centrifuged at 6,000 rpm for 5 min and
serum was transferred to a microcentrifuge tube.
At approximately 2 weeks following the last
immunization, progesterone (medroxyprogesterone acet-
ate, Depo-Provera; Pfizer) was administered subcutane-
ously (2.5 mg/dose) at 10 and 3 days before challenge.
Mice were challenged intravaginally (approximately
1 month following the last immunization) by direct instil-
lation of 10 μL of SPG containing 1x105 Ct serovar D EBs.
The vaginal vault and ectocervix were swabbed using a
microfiber swab (Fisher) on days 7, 11, 14, 18, and 21
(or a combination of these time points) following
challenge.
Swabs were placed into a 1.5-mL tube containing 2 ster-
ile glass beads (5 mm diameter) and 300 μL of Chlamydia
isolation medium (Trinity Biotech) on ice. Bacteria were
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eluted from the swabs and separated from cells by vortex-
ing for 60 s. 100 μL of eluted cells/bacteria were plated
onto a processing cartridge containing 100 μL of PBS and
stored at -70 °C until DNA extraction.
Primer, probe and real-time PCR
DNA from genital swab samples was extracted using the
MagNA Pure 96 DNA and Viral NA small volume kit
(Roche) on the MagNA pure machine (Roche) according
to the manufacturer’s instructions.
The oligonucleotide primer set was designed for
detection of all species of Chlamydiae. The sense primer,
16S DIR 5′-CGCCTGAGGAGTACACTCGC-3′, and
anti-sense primer, 16S Rev 5′-CCAACACCTCACGGCA
CGAG-3′, were designed to amplify a 208-bp fragment of
the Chlamydial 16S ribosomal subunit gene, conserved
across Chlamydia strains and serovars. Primers were
obtained from Sigma Genosys (The Woodlands, TX), and
the probe, 16S Fam-5′-CACAAGCAGTGGAGCATGTG
GTTTAA-3′ Tamra, was synthesized by Applied Biosys-
tems, (Foster City, CA).
The 50-μL reaction mixtures consisted of 1× QuantiTect
Multiplex PCR master mix without ROX (Qiagen),
100 nmol/L 16S probe, 200 nmol/L primer 16S DIR,
400 nmol/L primer 16S Rev, 30 nmol/L ROX reference
dye, and 5 μL of sample DNA. Nontemplate controls
consisting of the reaction master mix, primers, and
probe, but no DNA, were included in each assay run.
Reaction conditions were set as follows: 1 cycle at 95 °C
for 15 min, followed by 40 cycles at 94 °C for 1 min
and at 60 °C for 1 min. Thermal cycling, fluorescent
data collection, and data analysis were performed using
the Stratagene Mx3005P system (Stratagene) according
to the manufacturer’s instructions.
Detection of serum antibody and isotype levels by ELISA
Serum was analyzed by an enzyme-linked immunosorb-
ent assay (ELISA). Nunc ™ C96 Maxisorp Immunoplates
(Thermo Scientific) were coated with 50 μL of 1 μg/mL C.
trachomatis Serovar D EBs in PBS and refrigerated over-
night. The plates were washed three times with 0.05 %
Tween-20 (Fisher Scientific) in PBS (PBS-T). The wells
were blocked with 5 % HyClone® fetal bovine serum
(Thermo Scientific) in PBS at 200 μL/well for 1 h at room
temperature and washed three times with PBS-T. Serum
was diluted in 5 % FBS in PBS at a 1:500 dilution. Serially
diluted sera were added to the plate, incubated for 2 h at
room temperature and the plates were washed three times
with PBS-T. HRP-conjugated secondary antibodies (Goat
anti-mouse IgG, Fcγ fragment specific; Goat Anti-mouse
IgG, Fcγ Subclass 1 specific; or Goat Anti-mouse IgG, Fcγ
Subclass 2c specific; Jackson ImmunoResearch Laborator-
ies) were diluted in 5 % FBS in PBS at 1:6,000, 1:6,000, or
1:2,000 dilution, respectively. The diluted secondary
antibodies were added at 100 μL/well, incubated for 1 h at
room temperature and the plates were washed three times
with PBS-T followed by three times with PBS. Room
temperature BD Opt EIA™ TMB Substrate Reagent Set
(BD Biosciences) was mixed and filtered through a
0.22um CA filter unit (Corning), and 100 μL was added to
each well and incubated for 10 min at room temperature.
The reaction was stopped with 100 μL/well of 2 M H2SO4
(Fisher Scientific). The optical density (OD) was read at
450 nm on a SpectraMax® M5 (Molecular Devices). The
cutoff OD for each post-immunization serum was calcu-
lated as two times of the OD450 of the corresponding pre-
immunization serum. ELISA titers were determined by
linearly interpolating between the sequential log dilutions
that bracket the cutoff OD, where the dependent variable
is the OD response and the independent variable is the
log dilution. The resulting dilution is then back trans-
formed to obtain the reported titer. The reported titer is
the estimated dilution of serum that results in a response
equivalent to the cutoff OD.
Results
Expression of recombinant Chlamydia MOMP
Codon harmonization
To improve recombinant protein expression in a heterol-
ogous host, Angov et al. developed an algorithm termed
“codon harmonization” that best approximates codon
usage frequencies from the native host and adjusts
these for use in the heterologous system [26, 27]. We
performed either codon harmonization or standard codon
optimization on a recombinant Chlamydia muridarum
(Cm) MOMP gene and evaluated outer membrane ex-
pression with a whole cell flow cytometry antibody bind-
ing assay using in-house generated polyclonal mouse sera
against Chlamydia EB. Both codon type genes were
expressed in a pET vector expression system and with a
MOMP native leader sequence. We observed that codon
harmonization resulted in ~2 fold increase in geomean
fluorescence intensity (GFI) compared to the standard
host codon optimized gene (Fig. 1). Therefore, codon
harmonized genes were used in subsequent expression
evaluations (data below) to further improve rMOMP OM
expression.
Expression vector optimization
A panel of E. coli expression vectors were evaluated to
further increase the surface expression level of rMOMP
(Table 2). Recombinant C. trachomatis Serovar E (CtE)
MOMP with a PelB leader sequence was used in this
evaluation. The key elements that could affect the OM
expression include promoter strength and vector copy
number. We compared vectors with high, medium or low
copy numbers, and promoters of high, moderate or titrat-
able strength. We found that either a strong promoter or
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a high vector copy number limited the surface expression
of rMOMP using whole cell flow cytometry antibody
binding assay (Table 2). High rMOMP surface expression
can only be achieved with a combination of moderate pro-
moter and a low vector copy number (such as pAVE029),
suggesting that lower transcription level is preferred. Con-
sistent, rMOMP OM expression can be obtained with a
pACYDuet vector when we used a host strain with a con-
trollable RNA polymerase level to reduce the rMOMP
mRNA transcription rate.
Secretion leader sequence optimization
There are several advantages of secretory production of
recombinant membrane proteins compared to cytosolic
production. The N-terminal amino acid residue of the
secreted product can be identical to the natural gene
product after cleavage of the signal sequence by a specific
signal peptidase. Also, there appears to be much less
protease activity in the periplasmic space than in the
cytoplasm [29]. In addition, disulfide bonds formation can
be facilitated because the periplasmic space provides a
more oxidative environment than the cytoplasm [29].
Enhanced OM insertion and prevention of periplasmic
space inclusion bodies were investigated. Two amino
acids at the C-terminus of CtD-MOMP (C. trachomatis
Serovar D) were modified to improve the binding to
the E. coli β-barrel assembly complex protein (BamA),
which recognizes its outer membrane protein substrates
by a species-specific C-terminal signature motif [30].
However, we did not observe a difference in surface
expression levels between the wild type CtD-MOMP and
the C-terminus modified CtD-MOMP sequences (unpub-
lished observations). Different secretion leader sequences
reported to improve the OM localization of the target
protein were investigated by using a whole cell flow
cytometry antibody binding assay (Table 1). pAVE029
expression vector was used in this evaluation for Cm-
MOMP, CtE-MOMP and CtD-MOMP. Among tested
leader sequences, E. coli OmpA and OmpP leaders,
leader sequences from the omptins (SopA, PgtE, and
Pla), and PelB leader all resulted in detectable surface
expression of rMOMP. Native Cm-MOMP leader was
able to direct the OM expression for Cm-MOMP,
however, neither of native CtD- or CtE-MOMP leaders
resulted in the surface expression of rMOMP.
Expression condition optimization
Surface expression of rMOMP has been associated with
toxicity to the host cell, resulting in a low yield [22, 24,
25]. We evaluated a variety of cell culture conditions
with the pAVE029 expression system, including induc-
tion time and temperature, cell density at induction, and
cell culture medium (Fig. 2). rCtE-MOMP with a PelB
leader sequence was used in this evaluation. We per-
formed induction for 4 h, 6 h and 16 h under four differ-
ent temperatures: 16 °C, 25 °C, 30 °C and 37 °C. We
found that 4 h and 6 h resulted in comparable rMOMP
OM expression levels while no expression was observed















Fig. 1 Effect of codon usage harmonization on rMOMP surface
expression level. FACS geometric mean (geomean) fluorescence
intensity (GFI) is shown for harmonized or optimized rCm-MOMP
genes at T = 0 and T = 4 h after IPTG induction. Geometric means
of GFI from three independent experiments were plotted with
error bars representing standard deviation
Table 2 Evaluation of E. coli expression vectors
Vector Promoter/Strength Inducer Origin of Replication Copy Number rCtE-MOMP Surface
Expression (GFIa)
bpAVE029 λPL/Moderate IPTG pAT153(colE1) Low Good (~300)
pACYDuet-1 T7/Titratable Arabinose + IPTG p15A Low Intermediate (~120)
pET (pETBlue-1 and pET22b) T7/Strong IPTG pUC High Low (~30 or lower)
pWSK29 T7/T3/Strong IPTG pSC101 Low None (intracellular)
pJ831(pUC) T7/Titratable Rhamnose pMB1 High None (intracellular)
pJ841(pBR) T7/Titratable Rhamnose pMB1 Medium None (intracellular)
pJ851(pACYC) T7/Titratable Rhamnose p15A Low None (intracellular)
aGFI: geomean fluorescence intensity from whole cell flow cytometry antibody binding assay
bpAVE029 is an E. coli RNA polymerase dependent expression vector. Others listed are bacteriophage T7 RNA polymerase dependent expression vectors
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following 16 h induction at any of the temperatures
tested (Fig. 2a). Induction for 4 or 6 h at 37 °C or 30 °C
resulted in higher surface expression of rMOMP than
25 °C and no detectable surface expression was observed
at 16 °C (Fig. 2a). We also observed cell fragility at 37 °C
(but not at 30 °C), which was indicated by a decrease in
OD590 after induction (Fig. 2b). We performed induction
at different cell densities and found that it dramatically
impacts the rMOMP surface expression. The highest
rMOMP expression was obtained with an induction
OD590 of ~0.5, while expression dropped with an induc-
tion OD590 of ~0.8, while little or no surface expression
of rMOMP was observed with an induction OD590 of 1.2
or higher (Fig. 2c). We evaluated seven cell culture me-
diums and interestingly, the culture medium used had a
large impact on rMOMP OM expression (Fig. 2d). Low
levels of rMOMP OM expression were observed with
LB medium, 0.2 % lactose auto induction medium, 2YT
medium with 1 % glucose, and the chemically defined
Azura medium. The highest rMOMP OM expression
(GFI ~300 to 400 in the whole cell flow cytometry
antibody binding assay) was obtained with growth in
Cinnabar medium. We obtained very high level of periplas-
mic rMOMP expression with Progro medium, however, no
surface expression was observed. IPTG concentration for
induction was also evaluated and comparable rMOMP
b
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Fig. 2 Evaluation of expression conditions. rCtE-MOMP with a PelB leader sequence constructed in the pAVE029 vector was evaluated. a Surface
expression (FACS GFI) of rCtE-MOMP after different IPTG induction times (T = 0 and T = 4 h) when expressed at different temperatures (37 °C = circles,
30 °C = squares, 25 °C = triangles, 16 °C = downward pointing triangles). b Cell concentration (OD590) at different temperatures (37 °C = circles,
30 °C = squares) after different IPTG induction times (T = 0 and T = 4 h). Geometric means of three independent experiments were plotted
with error bars representing standard deviation. c Cell concentration (OD590) and surface expression (FACS GFI) at harvest with different cell
densities (OD590) at IPTG induction (T = 0). d Surface expression (FACS GFI) with different cell culture media. Geometric means of replicates
were plotted with error bars representing standard deviation
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OM expression was observed with 0.1 mM to 1 mM IPTG
(unpublished observations). Therefore, all expression stud-
ies described here were induced by addition of 0.4 mM
IPTG.
In summary, optimal conditions for rCtE-MOMP OM
expression was found to be induction for 4 h at 30 °C in
cells grown in Cinnabar medium when cell density
(OD590) reaches ~0.5 (Fig. 3). Three different rMOMP
proteins (Cm, CtD and CtE) have been successfully
expressed on E. coli outer membrane under these condi-
tions. rCtE-MOMP with a PelB leader sequence was used
for the subsequent purification, characterization and im-
munogenicity studies in this manuscript.
Purification and characterization of recombinant
Chlamydia MOMP
Following optimization of rCtE-MOMP OM expression,
the recombinant protein was purified. Harvested E. coli
cells expressing rMOMP were disrupted by microfludi-
zation and the membrane fraction containing rMOMP
was pelleted by ultra-centrifugation. Washing the mem-
brane fraction with high salt buffer further removed re-
sidual soluble cellular proteins. A subsequent wash with
a buffer containing 1 % Triton X-100 detergent removed
the bacterial inner membrane and a wash with a buffer
containing 3 % β-octyl-glucoside detergent removed cer-
tain bacterial outer membrane proteins other than recom-
binant MOMP. A variety of detergents were evaluated for
extraction of rMOMP from the outer membrane. We
found that sarkosyl (an anionic detergent) was the most
efficient, followed by foscholine-14 (a lipid like zwitter-
ionic detergent) and zwittergent 3–12. DTT was required
for extraction of rMOMP. Sarkosyl extracted rMOMP
was further purified by size exclusion and ion exchange
chromatography. Purified protein concentration was mea-
sured by amino acid analysis and the total yield of purified
rMOMP is about ~6 mg per liter of cell culture (mean
from three preparations).
The purified rCtE-MOMP migrates very similarly to
the native CtE-MOMP (nCtE-MOMP) that was purified
from Chlamydia EBs on a SDS-PAGE gel (Fig. 4a and
b). It appears that compared to nMOMP, rMOMP has a
slightly higher amount of dimeric and oligomeric forms
that are SDS-resistant and independent of disulfide
reductants (Fig. 4b). A western blot using antisera gen-
erated against outer membrane vesicles from the host
E. coli strain without the recombinant MOMP gene
showed that the purified rMOMP contained some co-
purified E. coli host proteins (Fig. 4c, sample 2), and the
purity is estimated to be about ~70 % as determined by
mass spectrometry (unpublished observations). We have
attempted to improve the purity of the preparation by
using different extraction and purification methods, how-
ever, were unable to further remove the co-purified host
proteins when the rMOMP protein is expressed without
an affinity tag. Complete processing of the PelB leader
sequence was confirmed by mass spectrometry (unpub-
lished observations). The endotoxin level in the final
purified protein sample is undetectable with an anti-
E.coli lipo-oligosaccharide (LPS) antibody on western
blot (Fig. 4d, sample 2).
To investigate whether the recombinantly expressed
rCtE-MOMP possessed β-strand secondary structure,
we performed circular dichroism (CD) analysis. CD
spectra of nMOMP and rMOMP both have a peak at
~215 nm which is the signature of β-strand structure
(Fig. 5). Interestingly, rMOMP appears to have a signifi-
cant higher mean molar ellipticity as compared to the
native MOMP. One possible explanation is that the re-
combinant and native MOMPs were extracted and puri-
fied differently, even though both were exchanged into the
same final storage buffer. The co-purified E. coli host pro-
teins might also contribute to the difference observed.
Mouse immunogenicity study
Our next goal was to evaluate the immunogenicity of
rCtE-MOMP in mice. Female C57BL/6 mice were im-
munized three times by subcutaneous (s.c.) routes with
purified nCtE-MOMP or rCtE-MOMP (10 μg/mouse/
immunization) in combination with an adjuvant contain-
ing CpG and Montanide on days 0, 20 and 30. A positive















10e0 10e1 10e2 10e3
Fluorescence Anti-CtE EB Negative
Intensity Mouse Sera Control
T=0 hr 3 3
T=4 hr (induced) 299 2
Fig. 3 Expression of rCtE-MOMP on E. coli outer membrane under
optimized expression conditions. An E. coli transformant expressing
rCtE-MOMP with a PelB leader constructed in a pAVE029 vector was
grown in Cinnabar medium at 37 °C and induced by 1 mM IPTG at
30 °C for 4 h when OD590 reaches ~0.5. Whole cell flow cytometry
antibody binding histograms were shown: red, anti-CtE EB mouse
sera and blue, a negative control antibody. Geomean fluorescence
intensities were also shown in table
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mouse by intraperitoneal (i.p.) route. A negative control
group (adjuvant control) was administered with a combin-
ation of CpG and Montanide only.
Post-immunization mouse serum was analyzed by
ELISA with CtD EBs as the coating antigen (Fig. 6). The
rMOMP immunized mice have comparable (no statis-
tical difference) IgGFcγ titers to the nMOMP immu-
nized group (Fig. 6a). We also tested subtypes of the
antibodies to evaluate whether the vaccine responses are
Th1 or Th2 biased. rCtE-MOMP elicited similar anti-
body profiles to the nMOMP immunized group (Fig. 6b).
These data suggested that the OM expressed rMOMP
elicits a similar antibody response in mice that react to
the native Chlamydia EB antigen, as compared to the
native MOMP.
Two weeks following the last immunization, mice were
challenged intravaginally with CtD EBs. The vaginal
vault and ectocervix were swabbed on multiple time
points (day 7 to day 21) following challenge. Previously,
a comparative analysis between a real-time quantitative
PCR (qPCR) and inclusion forming unit (IFU) measure-
ment was performed and no major differences between
the two assays were observed in monitoring infections
[31]. IFU analyis is more labor intensive, more subject-
ive, and not as high-throughput as qPCR. Therefore,
qPCR assay was chosen for evaluating our vaccines in
this study. rCtE-MOMP elicited significant reduction in
Chlamydial shedding compared to the adjuvant only
control group (P < 0.01) (Fig. 7). Moreover, the amount
of shedding after bacterial challenge in mice immunized
with rMOMP was comparable (similar bacterial load
post-challenge) to the amount observed in the nMOMP
immunized group (Fig. 7).
Discussion
E. coli has been the most prominent host system for
production of recombinant proteins [29, 32]. However,
the E. coli cytoplasmic expression system does have
some drawbacks. It is not suitable for production of
certain proteins, for example, proteins containing com-
plex disulfide bonds. Overexpressed proteins are often
produced in the form of inclusion bodies, from which
biologically active proteins can only be recovered by
complicated denaturation and refolding processes that

















Fig. 4 SDS-PAGE and western blot analysis of purified rCtE-MOMP. a SDS-PAGE; (b) anti-CtE EB mouse sera western blot; (c) anti-E.coli control
nOMV (native outer membrane vesicle from E. coli that does not contain recombinant MOMP gene) mouse sera; (d) anti-E.coli LPS monoclonal
antibody. Sample 1, control nCtE-MOMP; sample 2, purified rCtE-MOMP; sample 3, E. coli whole cell lysate; all samples were heated and reduced.



















Fig. 5 Secondary structure analysis of purified rCtE-MOMP with Circular
Dichroism Spectrometry. Mean molar ellipticity was plotted against
wavelength. Solid line, purified native CtE-MOMP; dashed line, purified
recombinant CtE-MOMP
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proteins adds additional complexity. We applied a variety
of techniques, including the adjustment of codon usage
bias, evaluation of different promoters and vectors with
different copy numbers to regulate the level of gene tran-
scription, evaluation of different leader sequences to guide
the secretion and insertion of the target protein into outer
membrane, and evaluation of cell culture medium and
optimization of cell culture conditions. In this paper, we
demonstrated significant improvement for the recombin-
ant expression of Chlamydia MOMP with some of the
techniques mentioned above.
Codon usage is a reflection of the relative amounts of
cognate aminoacyl tRNAs accessible in the cytoplasm.
The synonymous codon usage in all the organisms
displays a bias—some codons are used frequently, while
others are rarely used. Like others cellular systems, E.
coli also shows disparities for synonymous codons
where in general major codons are predominantly
present in highly expressed genes and rare codon oc-
curs in low level expressed genes. This disproportion of
codon frequency preferences becomes highly critical for
recombinant expression systems, and can lead to mRNA
instability, ribosomal stalling, translation errors or prema-
ture translational terminations, and ultimately failure to
express recombinant genes by heterologous expression
hosts. Reported studies indicated that folding and post-
translational modifications for both membrane and sol-
uble proteins are also susceptible to synonymous codon
usage [33]. Recent studies have shown that codon
harmonization, a methodology that matches the codon
usage in the recombinant host closely to the usage in
the gene’s native organism including the usage of low
abundance rare codons (unlike “codon optimization”
methodology that often excludes rare codons), can





























































Fig. 6 Serum antibody responses against CtD EB in immunized mice. a IgG Fcγ antibody titers; (b) IgG1/IgG2c ratios. Raw data were plotted on
Log10 scale with Box and Whisker Plots (Tukey), boxes =medians with interquartile (IQR) ranges, whiskers = 1.5 times the IQR distances. Transformed



























nCtE-MOMP + Mont + CpG




7 11 14 18 21
Group (Montanide + CpG)
nCtE-MOMP + Mont + CpG <0.0001***
rCtE-MOMP + Mont + CpG   0.0002***
CtD EBs <0.0001***
Fig. 7 Mouse challenge study. Average copy numbers from real-
time PCR for each immunization group were plotted on Log10
scale over the time course. Individual AUC (area under curve)
values were calculated for the entire time course and Wilcoxon
rank sum was used to determine the p-values for each group
(compared to Mont + CpG adjuvant control): * p < 0.05, ** p < 0.01,
*** p < 0.001, NS not significant
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significantly improve the yield and solubility of recombin-
ant proteins [26, 27]. Presumably by this codon selection,
pauses in the translation process are incorporated which
leads to improved protein folding and efficient protein
biosynthesis. In this study, we adapted the concept of
codon harmonization and demonstrated successful
recombinant expression of the Chlamydia MOMP, a
cysteine-rich, full-length β-barrel integral membrane
protein.
Outer membrane expression of β-barrel proteins in
gram-negative bacteria is complicated, involving trans-
lation, secretion across inner membrane into the peri-
plasmic space in the unfolded state, simultaneous
cognate chaperone assisted folding and insertion into
the outer membrane via β-barrel assembly machinery
(BAM) complex [34, 35]. Here, we evaluated different
promoters, vectors, leader sequences and cell culture
conditions for increased outer membrane rMOMP
expression. Our data suggested that the combination of
a moderate promoter and a low vector copy number
greatly improved rMOMP surface expression. We
hypothesized that slower transcription and therefore
slower translation is optimal for rMOMP OM expression
as it provides ample time to allow the newly synthesized
protein to be transported into the periplasmic space,
properly fold there and translocate onto the outer
membrane, resulting in an increased level of surface ex-
pression. We have also evaluated different secretion
leader sequences, as the efficiency of protein secretion
is affected by the leader sequence, even though many
prokaryotic and eukaryotic leader sequences are function-
ally interchangeable. We found that leader sequences
originated from the expression host E. coli, such as
OmpA and OmpP, drove higher levels of rMOMP sur-
face expression as compared to the native Chlamydia
leader sequences. Surface expression of rMOMP has
been associated with toxicity to the host cell [22, 24].
As we need to strike a balance between rMOMP OM
expression and the host cell viability, many factors need
to be optimized to achieve the best outcome, including
optimal cell culture medium, induction of protein ex-
pression on or before mid-log phase, and induction at a
certain temperature. Our data suggested that the higher
surface expression level of a membrane protein such as
MOMP can be achieved with a combination of molecu-
lar biology and cell culture techniques.
A well-known step along the protein folding pathway
that often requires catalysis in vivo is the cis/trans
isomerization of prolyl-iminopeptide bonds [36]. Four
peptidyl-prolyl cis/trans-isomerases (PPIases), SurA,
PpiD, FkpA and PpiA, have been described for the
isomerization role in periplasm of E. coli [37]. We
hypothesized that co-expression of these enzymes
might improve the efficiency of periplasmic folding of
rMOMP and therefore enhance its OM expression
level. In addition, proper disulfide bond formation is
also presumed to be critical for correct folding of
MOMP, a cysteine-rich protein. Both DsbA and DsbC,
members of the thioredoxin superfamily, are critical for
catalysis of correct disulfide bonds [38]. Another future
attempt will be to test the OM expression of rMOMP
in an E. coli host strain that overexpresses these
oxidoreductases.
Refolded rMOMP from E. coli inclusion bodies re-
sulted in a reduced level of protection compared to the
native MOMP in a mouse challenge model, suggesting
that correct conformation of MOMP is required for
protective immune responses [23]. Consistent with this
finding, rMOMP extracted from inclusion bodies and
refolded in vitro elicited a significant lower antibody
titer against Chlamydia EB (unpublished observations).
We showed here that OM expressed rMOMP main-
tained β-strand secondary structure as expected and
elicited a comparable antibody response in mice that
react to the native Chlamydia EB antigen, as compared
to the native MOMP. Whether the native tertiary struc-
ture is preserved in OM expressed rMOMP remains to
be determined, as no molecular structures of either native
MOMP or recombinant MOMP are available to date.
However, our data suggested that the OM expressed
rMOMP at least contains some epitopes in their native
forms.
Strains of Chlamydia trachomatis human serovars
have been used as the challenge strain in murine geni-
tal tract models, even though intravaginal inoculation
with human serovars typically results in a mild genital
tract infection of short duration and lower bacterial
burdens [39, 40]. We used C. trachomatis serovar D as
the challenge strain in our mouse immunogenicity
model, and demonstrated that immunization with either
native or OM expressed rMOMP resulted in similar low
levels of post-challenge bacterial burden, consistent with
the comparable antibody responses elicited from rMOMP
and nMOMP immunizations. A recent study in adaptive
immune deficient mice which lack mature T and B cell
immunity but maintain functional innate immune effec-
tors showed that C. muridarum infection was unable to
be resolved but C. trachomatis infection was spontan-
eously cleared, suggesting a possibility that innate immun-
ity is sufficient to clear the C. trachomatis infection in
mice [41]. Therefore, the comparison of vaccine efficacy
between recombinant and native MOMPs needs to be also
evaluated in the more stringent C. muridarum mouse
challenge model to further confirm the role of adaptive
immune response. However, the techniques that we ap-
plied to successfully achieve recombinant Chlamydia
MOMP outer membrane expression can serve as a
platform to produce other outer membrane proteins as
Wen et al. BMC Microbiology  (2016) 16:165 Page 11 of 13
vaccines or drug candidates and useful reagents for re-
search, as many of these are membrane proteins.
Conclusions
C. trachomatis MOMP is an immunodominant surface
protein of crucial importance in the immune response to
Chlamydia infection and also a major subunit vaccine tar-
get. Recombinant MOMP expressed in E. coli cytoplasm
forms inclusion bodies and rMOMP extracted from inclu-
sion bodies results in a reduced level of protection com-
pared to the native MOMP in a mouse challenge model.
Here we demonstrated successful recombinant expression
of MOMP on the E. coli outer membrane achieved with a
variety of techniques, including codon harmonization,
utilization of low copy number vectors and promoters
with moderate strength, suitable leader sequences and
optimization of cell culture conditions. The E. coli OM
expressed and purified rMOMP is immunogenic in mice
and elicits antibodies that react to the native antigen,
Chlamydia elementary body. Using C. trachomatis serovar
D as the challenge strain in our mouse immunogenicity
model, we demonstrated that immunization with either
native or OM expressed rMOMP resulted in similar low
levels of post-challenge bacterial burden. Surface expres-
sion of rMOMP on E. coli OM could provide useful re-
agents for vaccine research, and the methodology could
also serve as a platform to produce other outer membrane
proteins.
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